Definitive Healthcare (NASDAQ:DH - Get Free Report) is expected to announce its Q1 2025 earnings results after the market closes on Thursday, May 8th. Analysts expect Definitive Healthcare to post earnings of $0.02 per share and revenue of $56.20 million for the quarter. Definitive Healthcare has set its FY 2025 guidance at 0.190-0.220 EPS and its Q1 2025 guidance at 0.020-0.020 EPS.
Definitive Healthcare (NASDAQ:DH - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.04). Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. The firm had revenue of $62.29 million for the quarter, compared to analysts' expectations of $60.60 million. On average, analysts expect Definitive Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Definitive Healthcare Stock Up 3.3 %
NASDAQ DH traded up $0.09 on Friday, hitting $2.84. 369,226 shares of the stock were exchanged, compared to its average volume of 853,829. Definitive Healthcare has a fifty-two week low of $2.15 and a fifty-two week high of $7.47. The company has a 50-day moving average price of $2.79 and a 200-day moving average price of $3.93. The company has a market cap of $306.61 million, a PE ratio of -0.92, a PEG ratio of 4.06 and a beta of 1.48. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33.
Wall Street Analysts Forecast Growth
DH has been the topic of a number of recent analyst reports. The Goldman Sachs Group dropped their price objective on Definitive Healthcare from $4.50 to $3.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Barclays decreased their price objective on shares of Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a research note on Monday, March 3rd. Finally, Needham & Company LLC reissued a "hold" rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $5.35.
Get Our Latest Analysis on Definitive Healthcare
Definitive Healthcare Company Profile
(
Get Free Report)
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.
See Also
Before you consider Definitive Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Definitive Healthcare wasn't on the list.
While Definitive Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
